3-(吡啶-4-基)苄胺盐酸盐 | 864069-16-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 3-(吡啶-4-基)苄胺盐酸盐
• 英文名称: (3-(pyridin-4-yl)phenyl)methanamine hydrochloride
• 英文别名: 3-(4-Pyridyl)benzylamine hydrochloride；(3-pyridin-4-ylphenyl)methanamine;hydrochloride
• CAS: 864069-16-9
• 化学式: C₁₂H₁₂N₂*ClH
• 分子量: 220.702
• InChiKey: CIGOPDUVSVFYSW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.63
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  38.9
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  3-(吡啶-4-基)苄胺盐酸盐 在 碳酸氢钠 作用下， 以 甲醇 为溶剂， 生成 3-(4-吡啶基)苄胺
  参考文献：
  名称：

  Process for the preparation of tryptase inhibitors

  摘要：

  该发明涉及制备式I化合物及其盐的过程，这些化合物可用作曲激酶抑制剂，还涉及制备这些化合物的有用中间体、制备这些中间体的过程，以及利用这些中间体制备这些化合物的用途。

  公开号：

  EP1571150A1
• 作为产物：
  描述：

  3-(4-Pyridyl)benzaldehyde oxime hydrochloride 在 钯 氢气 作用下， 35.0 ℃ 、66.66 MPa 条件下， 生成 3-(吡啶-4-基)苄胺盐酸盐
  参考文献：
  名称：

  PROCESS FOR THE PREPARATION OF TRYPTASE INHIBITORS

  摘要：

  本发明涉及制备式I化合物或其盐的过程，该化合物可用作tryptase抑制剂，以及用于制备这种化合物的有用中间体，制备这种中间体的过程，以及用这种中间体制备这种化合物的用途。

  公开号：

  US20110015400A1

文献信息

• Non-systemic TGR5 agonists
  申请人：Venenum Biodesign, LLC

  公开号：US11236055B2

  公开（公告）日：2022-02-01

  The present invention relates to sulfonamide compounds of formula (I) and formula (II), or a pharmaceutically acceptable salt thereof. The present sulfonamide compounds are useful non-systemic TGR5 agonists that can be used to treat diabetic diseases in human. The present invention provides a pharmaceutical composition containing sulfonamide compounds of formula (I) and formula (II) and a method of making as well as a method of using same in treating patients inflicted with metabolic disorders by administering same. The compounds of the present invention may be used in combination with additional anti-diabetic drugs.

  本发明涉及式（I）和式（II）的磺酰胺化合物或其药学上可接受的盐。本发明的磺酰胺化合物是有用的非全身性 TGR5 激动剂，可用于治疗人类糖尿病疾病。本发明提供了一种含有式（I）和式（II）磺酰胺化合物的药物组合物及其制造方法，以及一种通过给药治疗代谢紊乱患者的方法。本发明的化合物可与其他抗糖尿病药物联合使用。
• [EN] NOVEL NON-SYSTEMIC TGR5 AGONISTS<br/>[FR] NOUVEAUX AGONISTES DE TGR5 NON SYSTÉMIQUES
  申请人：VENENUM BIODESIGN LLC

  公开号：WO2018005801A3

  公开（公告）日：2018-02-01
• NOVEL NON-SYSTEMIC TGR5 AGONISTS
  申请人：Venenum Biodesign, LLC

  公开号：US20200308122A1

  公开（公告）日：2020-10-01

  The present invention relates to sulfonamide compounds of formula (I) and formula (II), or a pharmaceutically acceptable salt thereof. The present sulfonamide compounds are useful non-systemic TGR5 agonists that can be used to treat diabetic diseases in human. The present invention provides a pharmaceutical composition containing sulfonamide compounds of formula (I) and formula (II) and a method of making as well as a method of using same in treating patients inflicted with metabolic disorders by administering same. The compounds of the present invention may be used in combination with additional anti-diabetic drugs.
• [EN] PROCESS FOR THE PREPARATION OF TRYPTASE INHIBITORS<br/>[FR] PROCESSUS POUR LA PREPARATION D'INHIBITEURS DE TRYPTASE
  申请人：AVENTIS PHARMA GMBH

  公开号：WO2005095385A1

  公开（公告）日：2005-10-13

  This invention is directed to processes for the preparation of compounds of the formula (I) and their salts, formula (I) which are useful as tryptase inhibitors, to intermediates useful in the preparation of such compounds, to processes for the preparation of such intermediates, and to the use of such intermediates for the preparation of such compounds.
• Process for the preparation of tryptase inhibitors
  申请人：Aventis Pharma Deutschland GmbH

  公开号：EP1571150A1

  公开（公告）日：2005-09-07

  This invention is directed to processes for the preparation of compounds of the formula I and their salts, which are useful as tryptase inhibitors, to intermediates useful in the preparation of such compounds, to processes for the preparation of such intermediates, and to the use of such intermediates for the preparation of such compounds.

  该发明涉及制备式I化合物及其盐的过程，这些化合物可用作曲激酶抑制剂，还涉及制备这些化合物的有用中间体、制备这些中间体的过程，以及利用这些中间体制备这些化合物的用途。